A Randomized Controlled Comparative Trial of Long-Acting Neuraminidase Inhibitor Laminavir Octanoate versus Zanamivir Hydrate in Influenza Virus Infectio
Not Applicable
- Conditions
- adult patients with influenza virus infection
- Registration Number
- JPRN-UMIN000004903
- Lead Sponsor
- Kameda Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are to be excluded from the trial; - if they reported influenza symptoms and had been treated with any antibiotics or antivirus medications within 1 week before enrollment, - if they had any chronic respiratory disease (bronchial asthma, chronic obstructive pulmonary disease)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the time to alleviation of influenza illness, which was defined as the interval between the start of the trial treatment and the start of the first 24 hour period in which influenza symptoms have improved to absent or mild
- Secondary Outcome Measures
Name Time Method the time to alleviation of influenza illness, which was defined as the interval between the start of the trial treatment and the start of the first 24 hour period in which axillary temperatures have returned to 36.9 celsius degree